HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM - Get Free Report) saw unusually-strong trading volume on Wednesday . Approximately 105,064 shares changed hands during trading, an increase of 5% from the previous session's volume of 100,338 shares.The stock last traded at $16.16 and had previously closed at $15.93.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on HCM shares. HSBC cut HUTCHMED from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Wall Street Zen raised HUTCHMED from a "buy" rating to a "strong-buy" rating in a research report on Friday, June 27th.
Read Our Latest Research Report on HCM
HUTCHMED Stock Performance
The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.70 and a current ratio of 2.83. The business has a 50 day moving average of $14.92 and a 200-day moving average of $14.71.
Hedge Funds Weigh In On HUTCHMED
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Barclays PLC raised its position in HUTCHMED by 1,483.6% during the 4th quarter. Barclays PLC now owns 2,407 shares of the company's stock valued at $35,000 after purchasing an additional 2,255 shares during the last quarter. Public Employees Retirement System of Ohio raised its position in HUTCHMED by 49.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock valued at $39,000 after purchasing an additional 899 shares during the last quarter. Summit Trail Advisors LLC raised its position in HUTCHMED by 7.7% during the 1st quarter. Summit Trail Advisors LLC now owns 14,094 shares of the company's stock valued at $212,000 after purchasing an additional 1,004 shares during the last quarter. OLD Mission Capital LLC bought a new position in HUTCHMED during the 4th quarter valued at approximately $230,000. Finally, Marshall Wace LLP bought a new position in HUTCHMED during the 4th quarter valued at approximately $261,000. 8.82% of the stock is currently owned by hedge funds and other institutional investors.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Stories
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.